EMEA-002166-PIP01-17-M02

Key facts

Active substance
lasmiditan
Therapeutic area
Neurology
Decision number
P/0291/2019
PIP number
EMEA-002166-PIP01-17-M02
Pharmaceutical form(s)
  • Tablet
  • Orodispersible tablet
Condition(s) / indication(s)
Treatment of migraine
Route(s) of administration
Oral use
Contact for public enquiries
Eli Lilly and Company Limited

E-mail: eu_paediatric@lilly.com
Tel. +44 (0)1276 4830 00

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating